- If you are wondering whether Innoviva's current share price still offers value after a strong run, this article walks through what the numbers are actually saying about the stock.
- Over the short term the stock has been mixed, with a 1.8% decline over the last 7 days. It currently sits at US$22.96 after returns of 17.4% over 30 days, 15.6% year to date, 28.1% over 1 year and 108.9% over 3 years, with a 99.5% return over 5 years.
- Recent coverage around Innoviva has focused on its positioning in the pharmaceuticals and biotech space and how investors are weighing that against its royalty and product portfolio. This helps frame these share price moves. While this news gives context, it does not answer the core question of what the stock might be worth today.
- On our valuation checks, Innoviva scores a solid 5/6 value score. Next we will look at the main valuation approaches behind that result, before closing with a way to assess value that goes beyond any single model.
Approach 1: Innoviva Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and discounting them back to today using a required return. It is essentially asking what those future dollars are worth in $ terms right now.
For Innoviva, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $189.4 million. Analysts and internal estimates project cash flows such as $181.6 million in 2026 and $173.5 million in 2030, with projections beyond the analyst horizon extrapolated by Simply Wall St.
When all those projected cash flows are discounted back and combined, the model arrives at an estimated intrinsic value of about $53.96 per share. Compared with the current share price of US$22.96, the DCF output suggests the stock trades at a 57.5% discount, which indicates it may be undervalued on this specific cash flow view.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Innoviva is undervalued by 57.5%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.
Approach 2: Innoviva Price vs Earnings
For a profitable company like Innoviva, the P/E ratio is a useful way to see what you are paying for each dollar of earnings. A higher or lower P/E often reflects what the market is building in for future growth and how risky those earnings are perceived to be, so there is no single "correct" P/E level for every stock.
Innoviva currently trades on a P/E of 6.33x. That sits well below the Pharmaceuticals industry average of 20.05x and also below the peer group average of 17.27x. On those simple comparisons, the stock looks cheap relative to many companies in the same space.
Simply Wall St also calculates a Fair Ratio, which is the P/E level it would expect for Innoviva given factors such as its earnings growth profile, profit margins, industry, market value and risk characteristics. Because it brings these company specific traits together, the Fair Ratio of 13.86x can be a more tailored yardstick than just lining up against broad industry or peer averages. Setting that 13.86x Fair Ratio beside the actual 6.33x P/E suggests Innoviva trades below what this framework would indicate.
Result: UNDERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.
Upgrade Your Decision Making: Choose your Innoviva Narrative
Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your own story about Innoviva tied to the numbers you think are reasonable for its future revenue, earnings, margins and fair value.
On Simply Wall St’s Community page, you can pick or create a Narrative that links what you believe about Innoviva’s business to a clear financial forecast and then to a Fair Value, so you are not just looking at ratios in isolation.
Each Narrative compares its Fair Value to today’s share price of US$22.96, which can help you decide whether Innoviva looks expensive, cheap or roughly in line with what you think it is worth, and these Narratives automatically refresh when new results, news or other material updates are added to the platform.
For example, one investor might back a higher Fair Value for Innoviva based on stronger long term cash flow assumptions. Another might choose a far lower Fair Value based on more cautious expectations for future earnings and margins, and both Narratives can sit side by side for you to weigh up.
Do you think there's more to the story for Innoviva? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com